{
    "id": 20210,
    "fullName": "KEAP1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "KEAP1 dec exp indicates decreased expression of the Keap1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9817,
        "geneSymbol": "KEAP1",
        "terms": [
            "KEAP1",
            "INrf2",
            "KLHL19"
        ]
    },
    "variant": "dec exp",
    "createDate": "03/26/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Arimidex (anastrozole) resistant breast cancer cells expressed lower levels of Keap1 than corresponding parental Arimidex (anastrozole) sensitive breast cancer cell lines in culture (PMID: 25976679).",
            "molecularProfile": {
                "id": 20651,
                "profileName": "KEAP1 dec exp"
            },
            "therapy": {
                "id": 633,
                "therapyName": "Anastrozole",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4830,
                    "pubMedId": 25976679,
                    "title": "Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25976679"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5002,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Femara (letrozole) resistant breast cancer cells expressed lower levels of Keap1 than corresponding parental Femara (letrozole) sensitive breast cancer cell lines in culture (PMID: 25976679).",
            "molecularProfile": {
                "id": 20651,
                "profileName": "KEAP1 dec exp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4830,
                    "pubMedId": 25976679,
                    "title": "Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25976679"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11910,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Xalkori (crizotinib) in a lung cancer cell line and patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28935,
                "profileName": "EML4 - ALK KEAP1 dec exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11911,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Zykadia (ceritinib) in patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28935,
                "profileName": "EML4 - ALK KEAP1 dec exp"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20651,
            "profileName": "KEAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28935,
            "profileName": "EML4 - ALK KEAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}